Pressure BioSciences confirmed the shipment of the Company’s first ever commercial production lot of a anoemulsion product created and enabled by the company’s Ultra Shear Technology nanoemulsification platform. The shipped product is a CBD oral spray designed by PBI for fast effect and high potency for Safer Medical of Montana, with whom PBI signed a multi-year development and manufacturing agreement, announced on May 4, 2022. SMM pre-paid the entire $75,000 purchase price of the Phase I production lot. The Agreement covers three phases of development and commercialization of a custom-formulated oral spray of hemp-derived nanoemulsified CBD designed for extremely rapid absorption and effectiveness, and for efficient high potency delivery of CBD active material in each dose. All ingredients used in the manufacture of this UltraShear prepared nanoemulsion product are sourced from naturally-occurring, plant-based origins. Phases II and III of the PBI-SMM Agreement are focused on scaling up UltraShear nanoemulsion production by a factor of 10x in each stage, with total PBI revenues captured under this Agreement expected to top $1M in Q1/Q2 of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly